US2011245470A1PendingUtilityA1
Immunoglobulins
Est. expiryMar 30, 2024(expired)· nominal 20-yr term from priority
Inventors:Jonathan Henry EllisAlexandre Eon-DuvalVolker GermaschewskiChristopher PlumptonNicholas T. RapsonMichael R. West
A61P 35/00A61P 37/00A61P 9/10A61P 43/00A61P 9/00A61P 29/00A61P 25/28A61P 25/04A61P 11/00A61P 11/06A61P 17/06A61P 19/02A61K 2039/505C07K 2317/33C07K 16/248C07K 2317/76C07K 2317/24A61K 39/395C07K 16/42C07K 16/24
41
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention concerns immunoglobulins, such as antibodies, which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and modulate the interaction between OSM and gp130. In typical embodiments, OSM is glycosylated. The invention also concerns antibodies that modulate the interaction between both Site II and Site III of OSM and their respective interacting partners. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
Claims
exact text as granted — not AI-modified1 . A competing antibody or antigen binding fragment which competitively inhibits the binding of a therapeutic antibody which specifically binds hOSM and modulates the interaction between hOSM and gp130 comprising a heavy chain of SEQ.I.D.NO: 11 and a light chain of SEQ.I.D.NO: 12 in an ELISA based assay with the proviso that the competing antibody does not comprise a CDRH3 of SEQ. I.D. NO: 42.
2 . A pharmaceutical composition comprising the competing antibody of claim 1 .Join the waitlist — get patent alerts
Track US2011245470A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.